医学
造血细胞
移植
内科学
淋巴瘤
肿瘤科
疾病
造血干细胞移植
外科
干细胞
造血
遗传学
生物
作者
Olivier Veilleux,Francisco Socola,Sally Arai,Matthew J. Frank,Laura Johnston,Robert Lowsky,Judith A. Shizuru,Everett Meyer,Lori Muffly,Andrew R. Rezvani,Parveen Shiraz,Surbhi Sidana,Saurabh Dahiya,David B. Miklos,Robert S. Negrin,Wen‐Kai Weng
摘要
Autologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T-cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders. However, a significant number of patients will experience post-AHCT disease relapse. Here, we report a retrospective study of consecutive 124 patients with PTCLs who underwent AHCT from 2008 to 2020. With a median follow-up of 6.01 years following AHCT, 49 patients (40%) experienced disease relapse. As expected, more patients who were not in first complete remission experienced post-AHCT relapse. Following relapse, majority of the patients (70%) receiving systemic therapies intended as bridging to curative allogeneic HCT. However, only 18 (53%) patients eventually underwent allogeneic HCT. The estimated 3-year OS among patients proceeding to allogeneic HCT was 72% (95% CI 46%-87%). Our report details the pattern of post-AHCT relapse and the management of relapsed disease using different therapeutic modalities.
科研通智能强力驱动
Strongly Powered by AbleSci AI